We analyse the case of Histocell, a biopharmaceutical company focused on the development of drugs and medical devices for regenerative medicine and cell therapy, from a corporate finance perspective. Firstly, we will explain the strategic rationale through the inauguration of its new production centre. Then, we will highlight the capital investment Histocell has received thanks to the Japanese investment fund Cell Innovation Partners, an operation that has made the opening of its new plant possible.
Get in touch with our experts.
We analyse the case of Histocell, a biopharmaceutical company focused on the development of drugs and medical devices for regenerative medicine and cell therapy, from a corporate finance perspective. Firstly, we will explain the strategic rationale through the inauguration of its new production centre. Then, we will highlight the capital investment Histocell has received thanks to the Japanese investment fund Cell Innovation Partners, an operation that has made the opening of its new plant possible.
The Basque biopharmaceutical company Histocell opened a new production centre in Larrabetzu dedicated to the manufacture of medical products for regenerative medicine.
Hostocell belongs to the NorayBio Group. This group was created in 2006 with the aim of bringing together innovative Basque biotech companies with an international vocation. The group, founded by Julio Font and Marta Acilu, currently includes three companies in the bioscience area located in the Science and Technology Park of Bizkaia: Noray Bioinformatics, Histocell and ArtinVet.
Histocell is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. Histocell began its trajectory in the Department of Cell Biology and Histology of the Faculty of Medicine and Odontology of the University of the Basque Country, to later set up in 2005 in the Science and Technology Park of Bizkaia. However, the aim of this new centre is to house research, production and marketing activities for its Reoxcare line of treatment for difficult-to-heal wounds and its Wharton Gel Complex and Histoessence dermocosmetic products.
In short, the creation of this plant has involved an investment of €1.6m and will generate 10 jobs at the start of its operation and, it is expected, around 30 in the coming years. With all this, the company forecasts sales of €6m by 2021.
The inauguration is not the only business milestone achieved by Histocell this year. The company has also carried out a capital increase for the opening of its new plant in which the Japanese investment fund Cell Innovation Partners has been brought in. This fund is related to Histocell's activity, as it also specialises in regenerative medicine and cell therapy. The main partners of this fund are the Japanese company Reprocell and Shinsei Bank.
On the one hand, Reprocell was founded in 2003 by Japanese university researchers. Later, it became the leading stem cell research company in Japan. In recent years, it expanded through a series of acquisitions to become REPROCELL Group Companies. In this way, each acquired company brings intellectual property and knowledge that helps amplify the value of the organisation. More recently, these companies have been integrated and consolidated into regional offices, and the names have become product and service brands.
On the other hand, Shinsei Banka Japanese financial institution offering a full range of financial products and services for institutional and individual clients. Shinsei combines its commercial and investment banking operations - with frequent investments in Europe - with an Institutional Banking division that engages in a wide range of commercial lending and equity investments. This division is affiliated with four subsidiary companies: Shinsei Investment Management, Shinsei Securities, Shinsei Servicer and Shinsei Trust and Banking.
Finally, Histocell has obtained the necessary investment to start up its new production centre in Larrabetzu, in which its partners and some institutional bodies such as the Provincial Council of Bizkaia and the Basque Government's Gauzatu programme, dedicated to promoting the creation and development of technology-based and innovative SMEs, have also participated.
The following table lists five international operations related to regenerative medicine. For example, Humacyte offers human tissue-based products for regenerative medicine and vascular surgery applications. The company, which was incorporated in 2004 and is based in North Carolina, has received 467.9M$.
| Company | Country | Description | Total amount of investment | Date of the last round |
|---|---|---|---|---|
| Dialpad | United States | Dialpad offers simplified cloud-based business phone solutions for every business. | $120M | 17/07/2018 |
| Wise | United Kingdom | Sabio is a unified communications and contact centre services company. | £50M | 11/07/2016 |
| Aircall | France | Aircall is an advanced call centre, full business phone and contact centre software natively integrated into any CRM. | $40,6M | 15/05/2018 |
| 3CLogic | United States | 3CLogic provides cloud-based multi-channel communications for helpdesk and sales organisations. | $11,5M | 22/08/2016 |
Investment analysis in the Dental Tech.Createch Medical and Straumann sectors.
Nokia buys health gadget company Withings and enters E-health world
Yes looking for investors, you want to buy or sell your company or finance your R&D&I project, get in touch with our Corporate Finance experts.
If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.
EN 
ES